Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Investments (2020 - 2025)

Gyre Therapeutics has reported Long-Term Investments over the past 11 years, most recently at $107.1 million for Q4 2025.

  • Quarterly Long-Term Investments rose 66.46% to $107.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.1 million through Dec 2025, up 66.46% year-over-year, with the annual reading at $107.1 million for FY2025, 66.46% up from the prior year.
  • Long-Term Investments was $107.1 million for Q4 2025 at Gyre Therapeutics, up from $64.3 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $107.1 million in Q4 2025 and troughed at $4.7 million in Q4 2023.
  • The 4-year median for Long-Term Investments is $52.5 million (2022), against an average of $54.2 million.
  • Year-over-year, Long-Term Investments crashed 88.38% in 2023 and then skyrocketed 1261.99% in 2024.
  • A 4-year view of Long-Term Investments shows it stood at $40.6 million in 2022, then crashed by 88.38% to $4.7 million in 2023, then skyrocketed by 1261.99% to $64.3 million in 2024, then surged by 66.46% to $107.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Long-Term Investments are $107.1 million (Q4 2025), $64.3 million (Q4 2024), and $4.7 million (Q4 2023).